A reduction of cardiovascular events risk while taking anti-inflammatory drugs has been demonstrated in several clinical studies—Canakinumab Anti-inflammatory Thrombosis Outcome Study (CANTOS) that used therapeutic monoclonal antibodies against IL-1β (canakinumab), and LoDoCo2 study where low doses of colchicine in patients with chronic CHD were used [37,38]. This evidence concerns the gene IL1B and deep vein thrombosis.